The global Xerostomia (dry mouth) market is anticipated to grow at a significant CAGR during the forecast period. The rising prevalence of Sjogren’s syndrome, where the immune cells of the body target the news cells which have salivary and tear glands is the major factor that is driving the global Xerostomia (dry mouth) market during the forecast period.
People suffering from this disease have a history of diseases like Sjogren’s syndrome or have undergone radiation therapy for head and neck cancer. According to NCBI, currently, around 15-20 million people are suffering from this disease. There has been an increase in the growing awareness regarding this disease and the other ailments associated with it.
Furthermore, with the increasing number of cancer chemotherapy, the risk of Xerostomia is also increasing as chemotherapy might lead to having thick saliva causing dry mouth which is driving the growth of the market. Some of the key global market players include GlaxoSmithKline Plc, Church & Dwight Co., Inc., Colgate-Palmolive Co., Sun Pharmaceuticals Industries Ltd., Lupin Pharmaceuticals, Inc., Pfizer, Inc., Parnell Pharmaceuticals, Inc., Acacia Pharma Group Plc, Quest Products, LLC (OraCoat), EUSA Pharma NP, and many others.
Market Coverage
o By Product Type
o By Type
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Xerostomia (Dry Mouth) Market by Segment
• By Product Type
o Artificial Saliva
o Dentifrices
o Salivary Stimulants
o Saliva Substitutes
o Salivary Pen
• By Application
o Prescribed Drugs
o OTC Drugs
Global Xerostomia (Dry Mouth) Market by Region
North America
Europe
Asia-Pacific
Rest of the World